Thursday, August 20, 2026

A new survey of otolaryngologists shows eight in ten warn that a proposed Medicare payment cut would reduce patient access to specialty care. While the specific CPT codes and magnitude of the cut are not detailed in the signal, the survey results indicate organized pushback from a major specialty society ahead of the 2027 Physician Fee Schedule final rule. Otolaryngology practices should monitor their specialty society (AAO-HNS) advocacy and prepare for potential reimbursement reductions in their highest-volume Medicare services. Audit your current Medicare procedure mix to model the financial impact of a 2-4% cut across your top codes.

A Kaiser Family Foundation survey indicates prior authorization denial rates across major insurers remain high, exceeding 18% for some plans. The data confirms that PA remains a persistent barrier to care and a primary source of administrative cost for practices. The survey, which likely builds on earlier KFF analyses, suggests payer scrutiny has not eased despite regulatory pressure and industry pledges to streamline the process. Practices should continue to track their own denial rates by payer and service line. Use this data to prioritize which payer contracts need renegotiation for clearer medical-necessity criteria or faster appeal pathways.

Community health clinics across Nevada warn that new state Medicaid policies will force them to downsize operations, putting patient access for low-income populations at risk. The state has revised its Medicaid reimbursement methodology for federally qualified health centers, prompting concerns about financial sustainability. Clinic administrators cite rising operational costs and say the payment changes, now taking effect, will not keep pace. Practice owners with a high Medicaid patient mix should review their state's Medicaid fee schedules and prepare for potential volume compression from referring clinics. The Nevada outcome signals a broader trend of states tightening Medicaid budgets, which can shift patient demand to private-practice settings.

Costco has filed for federal approval to launch co-branded Medicare Advantage plans in Arizona and Washington for the 2027 plan year. The retail giant is partnering with an existing health insurer to administer the plans, targeting its senior member base. This move follows a trend of non-traditional players like retailers and tech companies entering the MA market, aiming to leverage brand trust and existing customer relationships. For providers, new MA entrants can mean shifts in network contracting and patient attribution, though the operational impact will be limited initially to two states. Watch for CMS approval and the specific insurer partner, as that will determine the network and reimbursement model.

The Pharmaceutical Research and Manufacturers of America warns that the Biden administration's plan to codify Medicare drug price negotiation as a permanent program will worsen market distortions and chill innovation. CMS has proposed making the Inflation Reduction Act's negotiation framework a standing authority, beyond the initial ten drugs selected. PhRMA argues this creates long-term uncertainty for drug development and could limit future therapeutic options. For practices, the core dynamic remains: downward pressure on drug prices from Medicare negotiation may eventually influence commercial payer formularies and prior authorization rules for expensive therapies. The comment period on the proposal is ongoing; the final rule will shape the pharmaceutical landscape for years.